Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 230Breast Neoplasms 187Ovarian Neoplasms 113Neoplasms 100Neoplasm Metastasis 59Lung Neoplasms 54Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 44Stomach Neoplasms 41Parkinson Disease 4, Autosomal Dominant Lewy Body 41Endometrial Neoplasms 37Carcinoma, Ovarian Epithelial 32Squamous Cell Carcinoma of Head and Neck 28Uterine Cervical Neoplasms 24Esophageal Neoplasms 21Carcinoma 21Colorectal Neoplasms 20Recurrence 19Melanoma 18Esophageal Squamous Cell Carcinoma 18Small Cell Lung Carcinoma 16Pancreatic Neoplasms 16Head and Neck Neoplasms 14Solid Tumors 12Adenocarcinoma 12Advanced Solid Tumors 11Carcinoma, Renal Cell 10Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8Solid Tumor 8

Interventions

Paclitaxel 1Injections 1Docetaxel 1Bevacizumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Platinum-resistant Recurrent Ovarian Cancer × Paclitaxel × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡